154 related articles for article (PubMed ID: 32857943)
1. Brief overview of antibody-drug conjugate therapy for acute leukemia.
Walter RB
Expert Opin Biol Ther; 2021 Jul; 21(7):795-799. PubMed ID: 32857943
[No Abstract] [Full Text] [Related]
2. [Gemtuzumab ozogamicin and targeted cancer therapy].
Imaizumi M
Nihon Yakurigaku Zasshi; 2004 Jul; 124(1):25-9. PubMed ID: 15226619
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin.
Sabatino D; Henneman A; Ahmad S; Jou E; Goldberg B
J Oncol Pharm Pract; 2023 Jun; 29(4):840-845. PubMed ID: 35293248
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates in Myeloid Leukemias.
Senapati J; Daver NG; Pemmaraju N
Cancer J; 2022 Nov-Dec 01; 28(6):454-461. PubMed ID: 36383908
[TBL] [Abstract][Full Text] [Related]
5. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
6. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
7. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia in adults.
Goldenson BH; Goodman AM; Ball ED
Expert Opin Biol Ther; 2021 Jul; 21(7):849-862. PubMed ID: 32990476
[TBL] [Abstract][Full Text] [Related]
8. Gemtuzumab Ozogamicin Makes a Comeback.
Cancer Discov; 2017 Nov; 7(11):1208. PubMed ID: 28931515
[TBL] [Abstract][Full Text] [Related]
9. Dose-related efficacy and toxicity of gemtuzumab ozogamicin in pediatric acute myeloid leukemia.
Parigger J; Zwaan CM; Reinhardt D; Kaspers GJ
Expert Rev Anticancer Ther; 2016; 16(2):137-46. PubMed ID: 26646091
[TBL] [Abstract][Full Text] [Related]
10. Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
Baron J; Wang ES
Expert Rev Clin Pharmacol; 2018 Jun; 11(6):549-559. PubMed ID: 29787320
[TBL] [Abstract][Full Text] [Related]
11. Gemtuzumab ozogamicin for acute myeloid leukemia.
Appelbaum FR; Bernstein ID
Blood; 2017 Nov; 130(22):2373-2376. PubMed ID: 29021230
[TBL] [Abstract][Full Text] [Related]
12. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
13. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.
Castaigne S; Pautas C; Terré C; Raffoux E; Bordessoule D; Bastie JN; Legrand O; Thomas X; Turlure P; Reman O; de Revel T; Gastaud L; de Gunzburg N; Contentin N; Henry E; Marolleau JP; Aljijakli A; Rousselot P; Fenaux P; Preudhomme C; Chevret S; Dombret H;
Lancet; 2012 Apr; 379(9825):1508-16. PubMed ID: 22482940
[TBL] [Abstract][Full Text] [Related]
14. Are immunoconjugates approaching "standard of care" in AML?
Estey E
Best Pract Res Clin Haematol; 2013 Sep; 26(3):261-8. PubMed ID: 24309528
[TBL] [Abstract][Full Text] [Related]
15. Novel monoclonal antibody-based therapies for acute myeloid leukemia.
Morsink LM; Walter RB
Best Pract Res Clin Haematol; 2019 Jun; 32(2):116-126. PubMed ID: 31203993
[TBL] [Abstract][Full Text] [Related]
16. Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts.
Walter RB; Boyle KM; Appelbaum FR; Bernstein ID; Pagel JM
Blood; 2008 May; 111(9):4813-6. PubMed ID: 18326813
[TBL] [Abstract][Full Text] [Related]
17. ADCs Show Promise in Leukemias.
Cancer Discov; 2016 Sep; 6(9):939. PubMed ID: 27388473
[TBL] [Abstract][Full Text] [Related]
18. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
Cianfriglia M
Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Recurrent Refractory Pediatric Pre-B Acute Lymphoblastic Leukemia Using Inotuzumab Ozogamicin Monotherapy Resulting in CD22 Antigen Expression Loss as a Mechanism of Therapy Resistance.
Paul MR; Wong V; Aristizabal P; Kuo DJ
J Pediatr Hematol Oncol; 2019 Nov; 41(8):e546-e549. PubMed ID: 30807395
[TBL] [Abstract][Full Text] [Related]
20. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
